Novel 2-carbonyl analogues of diphenidol (1) - bearing lipophylic 1-substituents (2) - were synthesized starting from previously investigated diphenidol derivatives acting as M2-selective muscarinic antagonists. These compounds were tested for receptor binding affinity versus human muscarinic M1-M5 receptors stably expressed in CHO-K1 cells. Their activity in functional assays carried out on CHO-K1 cells expressing human M4 receptors (CHO-hM4) and on classical models of M1-M3 receptors, in guinea pig and rabbit tissue preparations, was also evaluated. Compound 2d showed an affinity of pKi = 7.73 at the human M4-receptor subtype with selectivity ratios ranging from 31-fold (M4/M5) to 60-fold (M4/M2). Interestingly this compound, in CHO-hM4 cells, blocked the inhibition of forskolin-activated cAMP accumulation produced by carbachol (IC50= 61 nM) whereas it was a weak muscarinic antagonist in functional tests carried out in guinea-pig and rabbit tissue expressing M1 (pKb = 5.96), M2 (pKb = 6.43) and M3 (pKb = 6.09) receptors. In conclusion, the modifications performed in this work on reference compounds led us to obtain surprisingly a M4 selective antagonist. Considering the therapeutic indications for M4 selective antagonists, compound 2d may serve as a novel lead compound for further optimization.
Synthesis and pharmacological profile of a series of 1-substituted-2-carbonyl derivatives of diphenidol: novel M4 muscarinic receptor antagonists
ANGELI, Piero;BUCCIONI, Michela;MARUCCI, Gabriella;
2008-01-01
Abstract
Novel 2-carbonyl analogues of diphenidol (1) - bearing lipophylic 1-substituents (2) - were synthesized starting from previously investigated diphenidol derivatives acting as M2-selective muscarinic antagonists. These compounds were tested for receptor binding affinity versus human muscarinic M1-M5 receptors stably expressed in CHO-K1 cells. Their activity in functional assays carried out on CHO-K1 cells expressing human M4 receptors (CHO-hM4) and on classical models of M1-M3 receptors, in guinea pig and rabbit tissue preparations, was also evaluated. Compound 2d showed an affinity of pKi = 7.73 at the human M4-receptor subtype with selectivity ratios ranging from 31-fold (M4/M5) to 60-fold (M4/M2). Interestingly this compound, in CHO-hM4 cells, blocked the inhibition of forskolin-activated cAMP accumulation produced by carbachol (IC50= 61 nM) whereas it was a weak muscarinic antagonist in functional tests carried out in guinea-pig and rabbit tissue expressing M1 (pKb = 5.96), M2 (pKb = 6.43) and M3 (pKb = 6.09) receptors. In conclusion, the modifications performed in this work on reference compounds led us to obtain surprisingly a M4 selective antagonist. Considering the therapeutic indications for M4 selective antagonists, compound 2d may serve as a novel lead compound for further optimization.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.